Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
Loading
EBITDA Over TimeExpanding
Percentile Rank86
3Y CAGR+34.1%
5Y CAGR+28.2%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+34.1%/yr
vs -23.6%/yr prior
5Y CAGR
+28.2%/yr
Recent acceleration
Acceleration
+57.7pp
Accelerating
Percentile
P86
Within normal range
vs 5Y Ago
3.5x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$195.99M+380.4%
2024$40.79M-59.5%
2023$100.84M+24.2%
2022$81.20M-43.1%
2021$142.77M+151.9%
2020$56.67M-93.5%
2019$876.12M+267.7%
2018$238.30M+193.6%
2017$81.15M+47.1%
2016$55.17M-